FMP010 / GSK, Kenya Medical Research Institute, United States Agency for International Development, Walter Reed Army Institute of Research, U.S. Army Medical Research and Development Command - LARVOL DELTA

Evaluate the Safety and Efficacy of Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered With Adjuvant AS01B (clinicaltrials.gov) - P1b; N=30; Completed; Sponsor: U.S. Army Medical Research and Development Command; Phase classification: P1 ➔ P1b

Clinical • Phase classification • Infectious Disease • Malaria

VBI Vaccines announces phase 2a clinical evaluation of VBI-1901 cancer vaccine candidate in combination with GSK’s AS01B adjuvant system in recurrent glioblastoma patients (Businesswire) - “VBI Vaccines Inc….announced a collaboration with GlaxoSmithKline (GSK) to clinically evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, with GSK’s proprietary AS01B adjuvant system. As part of the collaboration, VBI plans to add an additional study arm to Part B of the company’s ongoing, multi-center, open-label Phase 1/2a clinical study targeting recurrent glioblastoma (GBM), a cytomegalovirus (CMV)-associated tumor….Initiation of enrollment of the 10 patients in the VBI-1901 with AS01B arm is expected later in the second half of 2019, subject to U.S. Food and Drug Administration (FDA) acceptance of the amended protocol.”

Enrollment status • FDA event • Licensing / partnership